Elicera Therapeutics AB (publ) announced that it has received a so called "Notice of Allowance" from the Chinease Patent Office in its patent application relating to the use of the iTANK-technology in CAR T-cell therapies. Once granted, the patent can be kept in force until 2036.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.998 SEK | 0.00% | +11.14% | -78.11% |
Mar. 28 | Elicera Therapeutics AB Announces Director Changes | CI |
Mar. 06 | Elicera Enters Agreement with Prominent US Cancer Center to Evaluate the Use of ITANK in T-Cell Receptor Therapies | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-78.11% | 3.28M | |
+34.35% | 705B | |
+31.11% | 583B | |
-3.49% | 364B | |
+20.15% | 332B | |
+6.19% | 291B | |
+15.40% | 238B | |
-3.27% | 210B | |
+10.31% | 209B | |
+9.21% | 169B |
- Stock Market
- Equities
- ELIC Stock
- News Elicera Therapeutics AB
- Elicera Therapeutics Receives Notice of Allowance for Chinease Patent Protecting the iTANK Platform